160 related articles for article (PubMed ID: 37707674)
1. Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male Participants.
Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
Adv Ther; 2023 Nov; 40(11):4889-4906. PubMed ID: 37707674
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants.
Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
Adv Ther; 2024 Mar; 41(3):991-1009. PubMed ID: 38180721
[TBL] [Abstract][Full Text] [Related]
3. GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.
von Richter O; Skerjanec A; Afonso M; Sanguino Heinrich S; Poetzl J; Woehling H; Velinova M; Koch A; Kollins D; Macke L; Wuerth G
Br J Clin Pharmacol; 2017 Apr; 83(4):732-741. PubMed ID: 27790726
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults.
Tomaszewska-Kiecana M; Dryja A; Ullmann M; Petit-Frere C; Illes A; Dagres C; Monnet J
Expert Rev Clin Immunol; 2023 Apr; 19(4):447-455. PubMed ID: 36789991
[TBL] [Abstract][Full Text] [Related]
5. Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers.
Zheng Y; Abuqayyas L; Megally A; Fuhr R; Sałapa K; Downie J; Colice G
Clin Ther; 2021 Jan; 43(1):142-155.e5. PubMed ID: 33380362
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar Pegfilgrastim-cbqv Demonstrated Similar Immunogenicity to Pegfilgrastim in Healthy Subjects Across Three Randomized Clinical Studies.
Civoli F; Finck B; Tang H; Hodge J; O'Kelly H; Vexler V
Adv Ther; 2022 Mar; 39(3):1230-1246. PubMed ID: 35034311
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers.
Sangana R; Xu Y; Shah B; Tian X; Zack J; Shakeri-Nejad K; Kalluri S; Jones I; Ligueros-Saylan M; Taylor AF; Jain DK; Scosyrev E; Uddin A; Laurent N; Paganoni P
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):611-620. PubMed ID: 38389387
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects.
Shin D; Lee Y; Jeong D; Ellis-Pegler R
Drug Des Devel Ther; 2018; 12():3799-3805. PubMed ID: 30464411
[TBL] [Abstract][Full Text] [Related]
9. A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled Syringe.
Cherniakov I; Cohen-Barak O; Tiver R; Gillespie M; Kessler Y; Gutierrez M; Rasamoelisolo M; Li S; Shen H; Hallak H; Loupe PS; Smith M; Rabinovich-Guilatt L; Spiegelstein O
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1018-1027. PubMed ID: 33411992
[TBL] [Abstract][Full Text] [Related]
10. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects.
Bush J; Kawakami K; Muniz R
BMC Pharmacol Toxicol; 2019 Dec; 20(1):87. PubMed ID: 31888742
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and Pharmacodynamic Equivalence of Pegfilgrastim-cbqv and Pegfilgrastim in Healthy Subjects.
Finck B; Tang H; Civoli F; Hodge J; O'Kelly H; Vexler V
Adv Ther; 2020 Oct; 37(10):4291-4307. PubMed ID: 32789809
[TBL] [Abstract][Full Text] [Related]
12. Why Do the Majority of Submissions for Bridging from a Prefilled Syringe to an Autoinjector Include Bioequivalence Studies in Order to Demonstrate Comparability?
Lambert WJ
AAPS J; 2020 May; 22(3):72. PubMed ID: 32415524
[TBL] [Abstract][Full Text] [Related]
13. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta
Moosavi S; Borema T; Ewesuedo R; Harris S; Levy J; May TB; Summers M; Thomas JS; Zhang J; Yao HM
Adv Ther; 2020 Jul; 37(7):3370-3391. PubMed ID: 32524499
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of Subcutaneous Dupilumab Injection With an Autoinjector Device or Prefilled Syringe.
Cohen YZ; Zhang X; Xia B; Kosloski MP; Kamal MA; Davis JD; Kanamaluru V; Xu C
Clin Pharmacol Drug Dev; 2022 May; 11(5):675-681. PubMed ID: 35278283
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healthy adults.
Wynne C; Schwabe C; Stroissnig H; Dias R; Sobierska J; Guenzi E; Otto H; Sattar A; Haliduola HN; Edwald E; Berti F
Expert Opin Biol Ther; 2023; 23(8):773-780. PubMed ID: 36197309
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.
Waller CF; Tiessen RG; Lawrence TE; Shaw A; Liu MS; Sharma R; Baczkowski M; Kothekar MA; Micales CE; Barve A; Ranganna GM; Pennella EJ
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1087-1095. PubMed ID: 29671069
[TBL] [Abstract][Full Text] [Related]
17. A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects.
Sabet A; Dickerson DS; Kunina EE; Buccarello AL; Monnet J
Rheumatol Ther; 2022 Apr; 9(2):693-704. PubMed ID: 35262901
[TBL] [Abstract][Full Text] [Related]
18. Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe.
Yang BB; Morrow PK; Wu X; Moxness M; Padhi D
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1199-206. PubMed ID: 25894719
[TBL] [Abstract][Full Text] [Related]
19. Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects.
Davidson A; Brimhall D; Kay J; Keystone E; Lee SJ; Kim SH; Bae YJ; Choi EJ; Furst DE
Br J Clin Pharmacol; 2021 Nov; 87(11):4323-4333. PubMed ID: 33822406
[TBL] [Abstract][Full Text] [Related]
20. Usability of Prefilled Syringe and Autoinjector for SB4 (An Etanercept Biosimilar) in Patients with Rheumatoid Arthritis.
Rho YH; Rychlewska-Hańczewska A; Śliwowska B; Kim TH
Adv Ther; 2019 Sep; 36(9):2287-2295. PubMed ID: 31372961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
